Obermatt
See Similar Stocks →

Flags

Financial distress

Akebia Therapeutics

NAQ:AKBA · US00972D1054
BiotechnologySmall

360

34
Profit price97
Owner Earnings Yield1
Dividend Yield1
Price/Sales91
EV / Gross Profit71
Price/Book89
Return on Capital91
Cash Return on Capital74
Return on Equity25
EBIT Margin89
Gross Profitability91
Accruals78
Owner Earnings Margin83
Sales growth23
Profit growth76
Reinvestment10
Price momentum1
Debt load12
Refinancing5
Debt Payback1
Liquidity93
Analyst ratings55
Expectations trend50
Market mood68
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Akebia Therapeutics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2007
Employees244
Websiteakebia.com
ISINUS00972D1054
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
HematologyNephrologyChronic DiseasesCardiovascularHepatologyBiotechnologyHealth CareTherapeutics

Description

Akebia Therapeutics, Inc. (Akebia) operates as a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The company has built a business focused on developing and commercializing an innovativ…

Analysis

Quality compounder

Akebia Therapeutics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
22
2026

All-time high

22

Jun 2026

All-time low

1

Mar 2026

Average rank

12

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
91
—
—
—
Price/Earnings
64
—
—
—
Price/Book
89
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
92
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Akebia Therapeutics with its peers
Unicycive Therapeutics
NAQ:UNCY
85
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Rhythm Pharmaceuticals
NMQ:RYTM
31
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Alector
NSQ:ALEC
15
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ardelyx
NMQ:ARDX
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mineralys Therapeutics
NSQ:MLYS
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →